← All trials
NCT03722472
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2018
- Primary completion
- Mar 31, 2020
- Completion date
- Mar 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Immune DesignLead sponsor
- Immune DesignOverall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.